Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 4 | 2024 | 218 | 0.650 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 4 | 2016 | 17 | 0.640 |
Why?
|
| Haloperidol | 7 | 2019 | 36 | 0.610 |
Why?
|
| Quinolines | 5 | 2013 | 78 | 0.480 |
Why?
|
| Azepines | 4 | 2019 | 22 | 0.460 |
Why?
|
| Structure-Activity Relationship | 14 | 2019 | 506 | 0.400 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2016 | 83 | 0.390 |
Why?
|
| Indoles | 3 | 2014 | 187 | 0.380 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 15 | 0.370 |
Why?
|
| Benzothiazoles | 1 | 2012 | 26 | 0.370 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 65 | 0.360 |
Why?
|
| Antifungal Agents | 4 | 2013 | 169 | 0.330 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 1019 | 0.300 |
Why?
|
| Receptors, sigma | 2 | 2019 | 16 | 0.300 |
Why?
|
| Antipsychotic Agents | 5 | 2014 | 80 | 0.290 |
Why?
|
| Anti-Infective Agents | 2 | 2006 | 75 | 0.290 |
Why?
|
| Receptors, Serotonin | 3 | 2016 | 23 | 0.270 |
Why?
|
| Nanoparticles | 2 | 2023 | 460 | 0.260 |
Why?
|
| Alkaloids | 1 | 2006 | 46 | 0.250 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2024 | 9 | 0.210 |
Why?
|
| Quinolinium Compounds | 2 | 2013 | 9 | 0.210 |
Why?
|
| Ligands | 7 | 2019 | 388 | 0.190 |
Why?
|
| Drug Design | 3 | 2013 | 186 | 0.180 |
Why?
|
| Butyrophenones | 3 | 2011 | 8 | 0.170 |
Why?
|
| Fungi | 3 | 2013 | 106 | 0.160 |
Why?
|
| Fluorouracil | 3 | 2024 | 47 | 0.150 |
Why?
|
| Cell Survival | 4 | 2024 | 945 | 0.140 |
Why?
|
| Vero Cells | 4 | 2013 | 112 | 0.130 |
Why?
|
| Animals | 13 | 2023 | 16992 | 0.130 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2016 | 22 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 245 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2016 | 55 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 6644 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 2676 | 0.110 |
Why?
|
| Tropanes | 1 | 2014 | 7 | 0.110 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Acrylamides | 1 | 2014 | 14 | 0.110 |
Why?
|
| Molecular Structure | 5 | 2016 | 570 | 0.110 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cryptococcus | 1 | 2013 | 10 | 0.100 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 51 | 0.100 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2013 | 110 | 0.090 |
Why?
|
| Biological Products | 1 | 2013 | 91 | 0.090 |
Why?
|
| Indole Alkaloids | 2 | 2013 | 14 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2012 | 219 | 0.090 |
Why?
|
| Bacteria | 3 | 2013 | 293 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 139 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 432 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2010 | 301 | 0.080 |
Why?
|
| Plasmodium falciparum | 2 | 2006 | 144 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1124 | 0.070 |
Why?
|
| Humans | 10 | 2024 | 43102 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2024 | 1455 | 0.060 |
Why?
|
| Antiparasitic Agents | 1 | 2006 | 11 | 0.060 |
Why?
|
| Leishmania donovani | 1 | 2006 | 18 | 0.060 |
Why?
|
| Chemistry, Physical | 1 | 2006 | 50 | 0.060 |
Why?
|
| Isomerism | 1 | 2006 | 64 | 0.060 |
Why?
|
| Chemical Phenomena | 1 | 2006 | 56 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2006 | 61 | 0.060 |
Why?
|
| Antimalarials | 1 | 2006 | 64 | 0.060 |
Why?
|
| Microsomes, Liver | 1 | 2024 | 75 | 0.050 |
Why?
|
| Gadolinium | 1 | 2023 | 30 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2023 | 38 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1410 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2023 | 240 | 0.050 |
Why?
|
| Liposomes | 1 | 2023 | 132 | 0.050 |
Why?
|
| Apomorphine | 2 | 2014 | 13 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2023 | 347 | 0.040 |
Why?
|
| Binding Sites | 2 | 2016 | 671 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 157 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 98 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 1596 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 1766 | 0.030 |
Why?
|
| Dopamine Agents | 1 | 2016 | 28 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1082 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1568 | 0.030 |
Why?
|
| Catalepsy | 1 | 2014 | 9 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2014 | 7 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2014 | 109 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 82 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cricetinae | 1 | 2014 | 241 | 0.030 |
Why?
|
| Rats | 2 | 2014 | 3735 | 0.030 |
Why?
|
| Basidiomycota | 1 | 2013 | 12 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 45 | 0.030 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 30 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 437 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cyclization | 1 | 2010 | 50 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2011 | 169 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2010 | 62 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1081 | 0.020 |
Why?
|
| Candida albicans | 1 | 2010 | 176 | 0.020 |
Why?
|
| Clozapine | 1 | 2008 | 17 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 32 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 23 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 695 | 0.020 |
Why?
|
| Mitosporic Fungi | 1 | 2005 | 5 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 99 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 278 | 0.010 |
Why?
|
| Male | 1 | 2008 | 23409 | 0.000 |
Why?
|